Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Classical hematology 1

Conditions

Rare Diseases 1Pancreatic Neoplasms 1Gastrointestinal Diseases 1Crohn Disease 1Cachexia 1Anorexia 1Anemia 1

Interventions

ferric carboxymaltose 5Epoetin Alfa 2venetoclax 1trametinib 1ruxolitinib 1regorafenib 1ponatinib 1pertuzumab 1pembrolizumab 1palbociclib 1olaparib 1neratinib 1lorlatinib 1lenvatinib 1iron isomaltoside 1000 1idelalisib 1ferrous sulfate 1ferrous fumarate 1enzalutamide 1entrectinib 1enasidenib 1durvalumab 1dehydroftorafur 1darolutamide 1dacomitinib 1dabrafenib 1copanlisib 1cobimetinib 1cabozantinib 1cabazitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia × Infliximab × Gastrointestinal × Clear all
NCT00060502 2011-05-17

A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related Cachexia

Centocor, Inc.

Phase 2 Completed
73 enrolled
Classical hematologyGastrointestinal

Anemia, Anorexia, Cachexia, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡